FDA Tells Baxter To Tone Down Tisseel Marketing

Law360, New York (May 5, 2009, 12:00 AM EDT) -- The U.S. Food and Drug Administration has taken Baxter International Inc. to task over alleged overstatements contained in the company’s marketing material for Tisseel, a surgical sealant.

In a warning letter sent April 14 and released Tuesday, the FDA accused the company of making claims about Tisseel’s efficacy that are not supported by cited studies, and adopting a Tisseel tagline that suggests its use for procedures for which it has not been approved.

“The presentation, brochure and sell sheet are false or misleading because these materials,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.